Saxenda at two months: what liraglutide actually does to your weight

What did @siby3p actually say?

Honestly, the transcript here is largely inaudible or garbled, so pinning down specific claims is difficult. What we can work with is the video caption: two months on Saxenda (liraglutide), progress described as "vamos lento pero bien" (going slow but good), paired with hashtags referencing insulin resistance, diabetes, gym work, and weight loss. That framing, slow and steady progress on a GLP-1 medication combined with exercise, is actually a reasonable way to describe a liraglutide journey. The creator is not making dramatic cure claims. They appear to be documenting a personal experience.

Given the caption context, the implicit claims are: Saxenda causes gradual weight loss, it can be used alongside gym training, and it has relevance to insulin resistance. Those are the claims worth examining.

Does the science back this up?

Yes, largely. Liraglutide at 3.0 mg (the Saxenda dose) does produce gradual, modest weight loss in most people, and the evidence supports this being the expected pattern rather than a flaw. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed participants lost an average of 8 percent of body weight over 56 weeks, compared to about 2.6 percent with placebo. That is meaningful, but it is not dramatic, and it does accumulate slowly over months.

On insulin resistance: liraglutide improves insulin sensitivity as a secondary effect, documented in the SCALE trials and supported by Wadden et al., 2013 (Obesity). The gym hashtag is relevant too. Combining GLP-1 therapy with resistance training helps preserve lean muscle mass during weight loss, which is a real concern with these medications (Lundgren et al., 2023, Obesity Reviews). The creator pairing Saxenda with gym work is not just aesthetic, it is clinically smart.

What did they get wrong (or right)?

Based on available context, the creator got the core framing right. "Slow but good" is an accurate description of what liraglutide typically delivers. Where this video could mislead by omission is the dropout rate. The SCALE trials showed around 25 to 30 percent of participants discontinued due to side effects, primarily nausea and gastrointestinal symptoms. A progress video that only shows continued use implicitly suggests tolerability that is not universal.

There is also no mention of the dose titration protocol, which matters. Saxenda is started at 0.6 mg daily and increased weekly to 3.0 mg. Skipping that context means viewers watching this as a guide might not understand why their own experience differs. That said, this appears to be a personal diary post, not a medical guide, and the creator is not prescribing anything or making efficacy claims beyond their own experience. That is a meaningful distinction.

• Accurate: gradual weight loss framing matches clinical data
• Accurate: combining with gym work is supported by evidence
• Missing context: side effect rates and dose titration not addressed
• Missing context: liraglutide is less potent than newer GLP-1 agents like semaglutide

What should you actually know?

Saxenda (liraglutide 3.0 mg) is an older GLP-1 receptor agonist approved for weight management. It works. But compared to semaglutide (Wegovy) and tirzepatide (Zepbound), it produces less weight loss on average. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieving up to 22.5 percent body weight reduction, versus roughly 8 to 10 percent for liraglutide. That is not a knock on the creator, it is context anyone considering these medications deserves.

Insulin resistance and prediabetes are legitimate indications adjacent to liraglutide use. The medication does not cure insulin resistance, but it can improve it as part of a broader lifestyle intervention. If you are considering any GLP-1 therapy, that decision should involve a clinician who can assess your full health picture, not just a TikTok comment section. Two months in is also not enough time to evaluate long-term outcomes. Most clinical trials run 52 to 68 weeks for a reason.